Department of Otolaryngology-Head and Neck Surgery, Chonnam National University Medical School and Chonnam National University Hospital, Gwangju, Republic of Korea.
Department of Parasitology and Tropical Medicine, Chonnam National University Medical School, Hwasun-gun, Jeollanam-do, Republic of Korea,
Int Arch Allergy Immunol. 2021;182(5):381-387. doi: 10.1159/000511532. Epub 2020 Nov 11.
This study aimed to evaluate potential therapeutic effect of Metagonimus yokogawai on the OVA-induced allergic rhinitis model.
OVA-sensitized mice were used to assess potential therapeutic effect of the extract protein of M. yokogawai (My-TP). My-TP was administrated via the intralymphatic route to cervical lymph nodes. The frequencies of sneezing or nasal rubbing were recorded. Histopathologic evaluation was performed for eosinophil infiltrations in the tissues of the nasal mucosa and skin. The mRNA relative expressions of the cytokine profiles including Th1, Th2, Th17, and Treg subsets in the nasal mucosa, cervical lymph nodes, and spleen were analyzed by quantitative real-time reverse-transcriptase polymerase chain reaction. The potential underlying mechanism was investigated by examining cytokine profiles including IL-4 and Treg subsets from lymphocytes of the spleen by flow cytometry.
Intralymphatic injection of My-TP reduced allergic symptoms and eosinophil infiltration in the nasal mucosa. My-TP-treated group showed markedly decreased levels of OVA-specific IgE and WBC counts in nasal lavage. My-TP-treated group showed the decreased expression levels of IL-4, while those of IL-10 were increased in both the nasal mucosa. The levels of IFN-γ and IL-17 were also decreased in the nasal mucosa and cervical lymph nodes. The immunological mechanism may involve the downregulation of Th2 response and upregulation of Tregs in the nasal mucosa and cervical lymph nodes.
Our results provide the first evidence of potential therapeutic effect of M. yokogawai in OVA-sensitized allergic rhinitis mice, suggesting that a Treg/Th2 reorganization may play a role in clinical course of allergic rhinitis.
本研究旨在评估并殖吸虫对卵清蛋白（OVA）诱导的变应性鼻炎模型的潜在治疗作用。
采用 OVA 致敏小鼠，评估并殖吸虫提取物蛋白（My-TP）的潜在治疗作用。My-TP 通过颈淋巴结内淋巴管给药。记录打喷嚏或鼻摩擦的频率。对鼻黏膜和皮肤组织中的嗜酸性粒细胞浸润进行组织病理学评估。通过定量实时逆转录聚合酶链反应分析鼻黏膜、颈淋巴结和脾中细胞因子谱（包括 Th1、Th2、Th17 和 Treg 亚群）的 mRNA 相对表达。通过流式细胞术检查脾淋巴细胞中细胞因子谱（包括 IL-4 和 Treg 亚群）来研究潜在的作用机制。
经淋巴管内注射 My-TP 可减轻变应性症状和鼻黏膜嗜酸性粒细胞浸润。My-TP 治疗组的 OVA 特异性 IgE 和鼻洗液白细胞计数明显降低。My-TP 治疗组鼻黏膜 IL-4 水平降低，而 IL-10 水平升高。鼻黏膜和颈淋巴结中 IFN-γ 和 IL-17 水平也降低。免疫机制可能涉及鼻黏膜和颈淋巴结中 Th2 反应下调和 Treg 上调。
我们的研究结果首次提供了并殖吸虫在 OVA 致敏变应性鼻炎小鼠中具有潜在治疗作用的证据，表明 Treg/Th2 重排可能在变应性鼻炎的临床病程中发挥作用。
